$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000159075018000027 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$476.0K	$944.0K	$1.631M
YoY Change	-60.07%	-42.12%	74.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.700M	$2.700M	$2.500M
YoY Change	5.88%	8.0%	3.05%
% of Gross Profit
Research & Development	$8.234M	$7.399M	$5.018M
YoY Change	64.75%	47.45%	69.24%
% of Gross Profit
Depreciation & Amortization	$70.00K	$100.0K	$100.0K
YoY Change	-12.5%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$8.234M	$10.10M	$7.520M
YoY Change	64.75%	34.24%	49.86%
Operating Profit		-$9.151M	-$5.889M
YoY Change		55.39%	44.27%
Interest Expense	$140.0K	$140.0K	$60.00K
YoY Change	-566.67%	133.33%	160.87%
% of Operating Profit
Other Income/Expense, Net	$136.0K	$362.0K	$113.0K
YoY Change	-525.0%	220.35%	1514.29%
Pretax Income	-$10.32M	-$9.010M	-$5.830M
YoY Change	61.5%	54.55%	40.48%
Income Tax
% Of Pretax Income
Net Earnings	-$10.32M	-$9.011M	-$5.834M
YoY Change	61.56%	54.46%	40.48%
Net Earnings / Revenue	-2167.44%	-954.56%	-357.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.010M	-$4.395M	-$4.049M
COMMON SHARES
Basic Shares Outstanding	30.84M shares	30.60M shares	21.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.50M	$70.50M	$42.80M
YoY Change	31.86%	64.72%	692.59%
Cash & Equivalents	$32.61M	$31.70M	$42.81M
Short-Term Investments	$29.90M	$38.80M
Other Short-Term Assets	$2.900M	$3.800M	$3.000M
YoY Change	-3.33%	26.67%	650.0%
Inventory
Prepaid Expenses
Receivables	$24.00K	$1.382M	$635.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$65.37M	$75.75M	$46.42M
YoY Change	26.03%	63.18%	612.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$727.0K	$751.0K	$610.0K
YoY Change	29.13%	23.11%	-39.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$777.0K	$801.0K	$660.0K
YoY Change	26.75%	21.36%	-35.86%
TOTAL ASSETS
Total Short-Term Assets	$65.37M	$75.75M	$46.42M
Total Long-Term Assets	$777.0K	$801.0K	$660.0K
Total Assets	$66.15M	$76.55M	$47.08M
YoY Change	26.04%	62.6%	524.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$571.0K	$1.206M	$409.0K
YoY Change	-36.98%	194.87%	701.96%
Accrued Expenses	$3.868M	$4.336M	$4.142M
YoY Change	29.32%	4.68%	151.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$2.300M	$1.300M	$2.000M
YoY Change		-35.0%
Total Short-Term Liabilities	$6.733M	$6.833M	$6.534M
YoY Change	72.77%	4.58%	129.02%
LONG-TERM LIABILITIES
Long-Term Debt	$8.000M	$8.900M	$1.400M
YoY Change	-19.19%	535.71%
Other Long-Term Liabilities	$66.00K	$88.00K	$171.0K
YoY Change	-56.58%	-48.54%	8450.0%
Total Long-Term Liabilities	$66.00K	$88.00K	$171.0K
YoY Change	-56.58%	-48.54%	8450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.733M	$6.833M	$6.534M
Total Long-Term Liabilities	$66.00K	$88.00K	$171.0K
Total Liabilities	$14.80M	$15.84M	$8.096M
YoY Change	5.96%	95.59%	183.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.3M	-$116.0M	-$87.21M
YoY Change	34.94%	32.99%	247.83%
Common Stock	$308.0K	$308.0K	$219.0K
YoY Change	36.28%	40.64%	102.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$51.34M	$60.72M	$38.99M
YoY Change
Total Liabilities & Shareholders Equity	$66.15M	$76.55M	$47.08M
YoY Change	26.04%	62.6%	524.33%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$10.32M	-$9.011M	-$5.834M
YoY Change	61.56%	54.46%	40.48%
Depreciation, Depletion And Amortization	$70.00K	$100.0K	$100.0K
YoY Change	-12.5%	0.0%	0.0%
Cash From Operating Activities	-$8.170M	-$6.800M	-$5.660M
YoY Change	12.69%	20.14%	405.36%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$200.0K	-$60.00K
YoY Change	50.0%	233.33%
Acquisitions
YoY Change
Other Investing Activities	$9.140M	-$5.800M	$0.00
YoY Change
Cash From Investing Activities	$9.090M	-$6.020M	-$60.00K
YoY Change	-22825.0%	9933.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	1.120M	2.200M
YoY Change	-100.08%	-49.09%	-11100.0%
NET CHANGE
Cash From Operating Activities	-8.170M	-6.800M	-5.660M
Cash From Investing Activities	9.090M	-6.020M	-60.00K
Cash From Financing Activities	-10.00K	1.120M	2.200M
Net Change In Cash	910.0K	-11.70M	-3.520M
YoY Change	-80.3%	232.39%	208.77%
FREE CASH FLOW
Cash From Operating Activities	-$8.170M	-$6.800M	-$5.660M
Capital Expenditures	-$60.00K	-$200.0K	-$60.00K
Free Cash Flow	-$8.110M	-$6.600M	-$5.600M
YoY Change	12.48%	17.86%	400.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30839463	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
	dei	Entity Small Business EntitySmallBusiness	true
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	5000	USD
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	0	USD
CY2017Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	185000	USD
CY2018Q3	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	358000	USD
CY2017Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	197000	USD
CY2018Q3	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	284000	USD
CY2017Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2018Q3	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2017Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	581000	USD
CY2018Q3	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	2005000	USD
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	0	USD
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	55000	USD
CY2018Q3	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2017Q4	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	1100000	USD
CY2018Q3	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	800000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	645000	USD
	us-gaap	Interest Paid Net InterestPaidNet	112000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2994000	shares
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	51000	USD
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3566000	shares
	mgen	License Fee Expense Milestone Reached LicenseFeeExpenseMilestoneReached	700000	USD
CY2017Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	41000	USD
CY2018Q3	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	285000	USD
CY2017Q3	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	101000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176395000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2742000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2018Q3	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1693000	USD
CY2017Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	74000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2742000	USD
CY2018Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	83000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4336000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	232000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
	mgen	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding	0.04
CY2018Q3	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	1840317	shares
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	906000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1206000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1456000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1382000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	229000	USD
	us-gaap	Accretion Expense AccretionExpense	85000	USD
	us-gaap	Accretion Expense AccretionExpense	283000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2991000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2835000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3015000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	131877000	USD
CY2017Q4	us-gaap	Assets Assets	52481000	USD
CY2018Q3	us-gaap	Assets Assets	76553000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	51868000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	75752000	USD
CY2018Q3	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2018Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38800000	USD
CY2018Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38800000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1280000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42805000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47441000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31700000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	20701000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-15741000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	722269	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	308000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5834000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20126000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9021000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22392000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2018Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22568006	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30833367	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22568006	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30833367	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	226000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	119000	USD
CY2018Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	80000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	13000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227000	USD
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	206000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1538000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1259000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M1D
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2502000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8364000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2696000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8354000	USD
CY2017Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	193000	USD
	us-gaap	Interest Paid Net InterestPaidNet	358000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-598000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	287000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	615000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-74000	USD
CY2018Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	222000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-871000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1281000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	719000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	927000	USD
CY2017Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	58000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13971000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	15835000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52481000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76553000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3897000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6833000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	10000000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3667000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4000000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2333000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9922000	USD
CY2018Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	8914000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40557000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41926000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1068000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38998000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20924000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18669000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5834000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20126000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-9011000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22386000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5834000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20131000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9011000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22386000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1076000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	245000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	362000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	890000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	9922000	USD
CY2018Q3	us-gaap	Notes Payable NotesPayable	10205000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2018Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1291000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7520000	USD
	us-gaap	Operating Expenses OperatingExpenses	22989000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	10095000	USD
	us-gaap	Operating Expenses OperatingExpenses	30541000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5889000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20178000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9151000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22631000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	780000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	99000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	277000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	404000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	164000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-6000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	88000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38604000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	212000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	394000	USD
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2971000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3843000	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	110000	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	242000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	220000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	179000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3398000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3766000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	563000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	751000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	76981000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1500000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5018000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14625000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7399000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22187000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93593000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115979000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1631000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2811000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	944000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7910000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1693000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2742000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	902720	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4182404	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	38827000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	242000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	179000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	38510000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	60718000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	5000	USD
CY2018Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21572498	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18215857	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30723704	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29182872	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-18-000027-index-headers.html	Edgar Link	pending
0001590750-18-000027-index.html	Edgar Link	pending
0001590750-18-000027.txt	Edgar Link	pending
0001590750-18-000027-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-09302018x10q.htm	Edgar Link	pending
mgen-09302018xex102.htm	Edgar Link	pending
mgen-09302018xex311.htm	Edgar Link	pending
mgen-09302018xex312.htm	Edgar Link	pending
mgen-09302018xex321.htm	Edgar Link	pending
mgen-20180930.xml	Edgar Link	completed
mgen-20180930.xsd	Edgar Link	pending
mgen-20180930_cal.xml	Edgar Link	unprocessable
mgen-20180930_def.xml	Edgar Link	unprocessable
mgen-20180930_lab.xml	Edgar Link	unprocessable
mgen-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2018 Q4 Form 10-Q Financial Statement

#000159075018000027 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2018 Q4 Form 10-Q Financial Statement

#000159075018000027 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn